Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2020;383:30 de diciembre. [Ref.ID 103836]

Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Rajagopalan B, On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias. A scientific statement from the American Heart Association. Circulation 2020;142:16 de septiembre. [Ref.ID 103712]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

Anónimo. Éribuline et liposarcome inopérable réfractaire ou en rechute. Prescrire 2017;37:416-7. [Ref.ID 102000]

Anónimo. Érythrodysesthésies palmoplantaires des antitumoraux anti-VEGF. Prescrire 2017;37:30-1. [Ref.ID 101368]

Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]

Anónimo. Bévacizumab et cancer épithélial de l'ovaire résistant aux sels de platine. Prescrire 2015;35:656-7. [Ref.ID 99713]

Anónimo. Cabozantinib. Prescrire 2015;35:650-3. [Ref.ID 99710]

Hawkes N. NHS England drops 16 medicines from Cancer Drugs Fund. BMJ 2015;351:h4803. [Ref.ID 99469]

Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Messner J, Wilhelm M, Koch P, Lindemann H-W, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, on behalf of the German Hodgkin Study Group the Swiss Group for Clinical Cancer Research the Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015;385:1418-27. [Ref.ID 99035]

Casasnovas O, Coiffier B. Hodgkin's lymphoma: better outcomes with fewer drugs?. Lancet 2015;385:1371-3. [Ref.ID 99032]

Casassus B. Europe urged to take action on drug shortages. Lancet 2015;385:1279-80. [Ref.ID 99016]

Robak T, Huang H, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F, for the LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015;372:944-53. [Ref.ID 98932]

Anónimo. Bortézomib en association dans le myélome multiple. Prescrire 2015;35:182-3. [Ref.ID 98926]

Anónimo. Britain’s NHS cuts funding for costly cancer medicines. DIA Daily 2015:13 de enero. [Ref.ID 98704]

Anónimo. Lésions de la muqueuse oesophagienne d'origine médicamenteuse. Prescrire 2014;34:905-10. [Ref.ID 98473]

Anónimo. Atteintes des ongles d'origine médicamenteuse. Prescrire 2014;34:191-4. [Ref.ID 97362]

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-26. [Ref.ID 95505]